Press Releases G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
4.31 ^USD	-4.86%		-8.10%	+41.31%

May. 22	Sector Update: Health Care Stocks Lower Premarket Wednesday	MT
May. 22	G1 Therapeutics Grants Deimos Biosciences License to Market Anti-Radiation Treatment -- Shares Up Pre-Bell	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit	May. 22	AQ
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses	May. 22	GL
Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	May. 14	AQ
G1 Therapeutics : May 2024 Corporate Presentation	May. 08	PU
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 01	AQ
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights	May. 01	GL
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib	May. 01	GL
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024	Apr. 17	AQ
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Apr. 04	AQ
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 01	AQ
G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	Mar. 04	AQ
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 01	AQ
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	Feb. 28	GL
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	Feb. 27	AQ
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024	Feb. 15	AQ
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee	Feb. 12	GL
Life Sciences Ontario Announces Recipients of 2024 LSO Awards	Jan. 16	AQ
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	GL
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	AQ
G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	Jan. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Press Releases

Filters